PRESENTATION
Q1 2024 — Presentation
Q1 2024PDF · 33 pages2.8 MB
Merck Q1 2024 Earnings April 25, 2024 -- 1 of 33 -- Agenda 2 Strategy and Business Update Rob Davis Chairman and Chief Executive Officer Question & Answer Session Business/Financial Results and Outlook Caroline Litchfield Chief Financial Officer Research Update Dr. Dean Li President, Merck Research Laboratories -- 2 of 33 -- Forward-looking statement of Merck & Co., Inc., Rahway, N.J., USA 3 This presentation of Merck & Co., Inc., Rahway, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions. The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s Annual Report on Form 10-K for the year ended December 31, 2023 and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov). -- 3 of 33 -- Strategy and Business Update Rob Davis Chairman and Chief Executive Officer -- 4 of 33 -- Delivered on our key strategic priorities in Q1 2024 Advanced the pipeline to meet patient unmet need Achieved strong commercial and financial performance Executed on strategic business development to augment pipeline Created long-term value for patients and shareholders 5 -- 5 of 33 -- 20,000 30,000 40,000 50,000 60,000 70,000 2022 2023 2024 Strong Q1 sales1 and earnings growth 6 1. Results from continuing operations attributable to Merck & Co., Inc. 2. Merck does not exclude expenses for upfront and milestone payments related to certain collaborations and licensing agreements, or charges related to pre-approval assets obtained in transactions accounted for as asset acquisitions from its non-GAAP results. First quarter of 2024 and 2023 include $0.26 and $0.52 per share of such charges, respectively. Full year non-GAAP outlook for 2024 and full year reported results for 2023 and 2022 include $0.26, $6.21 and $0.22 per share of such charges, respectively. 3. GAAP EPS $1.87. $15.8B +9% +12% ex-Exchange Q1 Worldwide Sales Q1 Non-GAAP EPS3 $5.37 Full Year Sales Full Year Non-GAAP EPS2 $59.3B +22% $60.1B +1% 2022 2023 2024 $1.51 $7.48 GUIDANCE RANGE $63.1B - $64.3B +5% - +7% GUIDANCE RANGE $8.53 - $8.65 $2.07 +48% Includes one-time charge of $0.26 related to the Harpoon acquisition -- 6 of 33 -- Maximizing potential impact for patients with cutting-edge science Vaccines HPV & Pneumococcal Seeking to protect broad populations globally Oncology Diverse Portfolio & Pipeline Expanding our impact to more patients with potential to improve outcomes Infectious Disease HIV Progressing our clinical programs focused on the treatment and prevention of HIV 7 -- 7 of 33 -- Positioned to deliver the next wave of important innovations Creating a sustainable innovation engine that, with continued clinical success, will lead to a more diversified portfolio of growth drivers over the next decade and beyond “ ” 8 -- 8 of 33 -- Business/Financial Results and Outlook Caroline Litchfield Chief Financial Officer -- 9 of 33 -- Strong Q1 worldwide sales growth 10 Merck WORLDWIDE SALES1,2 $15.8B+9% growth +12% ex-exchange3 $14.0B +10% growth +13% ex-exchange3 Human Health $1.5B +1% growth +4% ex-exchange3 Animal Health 1. Results attributable to Merck & Co., Inc. 2. Worldwide Sales includes Other Revenue. 3. Updated May 6, 2024: ~2% of the negative impact of foreign exchange for Worldwide Sales and Human Health, and ~3% of the negative impact of foreign exchange for Animal Health, was due to devaluation of Argentine peso, which was largely offset by inflation-related price increases, consistent with practice in that market. -- 10 of 33 -- Oncology: KEYTRUDA continues to drive excellent growth 11 Growth rates exclude the impact of foreign exchange. 1. ~4% of the negative impact of foreign exchange was due to devaluation of Argentine peso, which was largely offset by inflation-related price increases, consistent with practice in that market. • KEYTRUDA sales of $6.9B increased 24% 1 year-over-year, driven by uptake in earlier stage cancers and continued strong demand from metastatic indications – In the U.S., increase largely attributable to indications in earlier stage NSCLC following launches of KN-671 and KN-091, as well as strong uptake following launch of KN-A39 in advanced urothelial cancer – Ex-U.S. growth reflects continued uptake in earlier stage cancers, including high-risk early- stage TNBC and adjuvant RCC, as well as demand from metastatic indications $4.2B +20% $3.4B +31% $5.3B +30% 1Q22 1Q23 1Q24 $4.8B +27% $5.8B +24% $6.9B +24% -- 11 of 33 -- Oncology: Strong performance across broad portfolio • Lynparza 1 sales grew 7%, driven primarily by higher demand in certain international markets • Lenvima 2 sales grew 10%, driven primarily by higher demand in the U.S. • WELIREG sales more than doubled, driven by the approval of LITESPARK-005 for certain patients with previously treated advanced RCC, as well as increased uptake in VHL disease-associated tumors $181M +15% $151M +57% 12 Growth rates exclude the impact of foreign exchange. 1. In collaboration with AstraZeneca 2. In collaboration with Eisai 1Q22 1Q23 1Q24 $275M +8% $266M +20% $292M +7% 1Q22 1Q23 1Q24 $232M +5% $227M +77% $255M +10% 1Q22 1Q23 1Q24 $42M +128% $18M $85M +102% -- 12 of 33 -- Vaccines: Robust growth driven by GARDASIL 13 • GARDASIL sales of $2.2B increased 17% year-over-year driven by global demand – Sales benefited from timing of shipments in China and CDC purchasing patterns in the U.S. • VAXNEUVANCE grew to $219M, driven by continued uptake of pediatric indication in the U.S. and ongoing launches in Europe – Sales benefited from CDC purchasing patterns in the U.S. $1.2B +78% $656M -24% $1.7B +40%$1.5B +6% $1.5B +50% $1.9B +27% Growth rates exclude the impact of foreign exchange. 1Q22 1Q23 1Q24 $1.5B +60% $2.0B +43% $2.2B +17% -- 13 of 33 -- Animal Health: Growth across livestock and companion animal 14 • Animal Health sales increased 4% 1 to $1.5B – Livestock sales growth was driven by price actions, as well as demand for swine and poultry products, partially offset by lower demand for ruminants products – Companion Animal growth reflects price actions 1Q22 1Q23 1Q24 $1.5B +9% $1.5B +5% $1.5B +4% Growth rates exclude the impact of foreign exchange. 1. Updated May 6, 2024: ~3% of the negative impact of foreign exchange was due to devaluation of Argentine peso, which was largely offset by inflation-related price increases, consistent with practice in that market. -- 14 of 33 -- Q1 2024 non-GAAP financial results summary1 Q1 2024 Q1 2023 Change Change Ex-FX Sales $15.8 $14.5 +9% +12% Non-GAAP Gross Margin 81.2% 76.9% +4.3pts +3.8pts Non-GAAP Operating Expenses $6.4 $6.7 -4% -3% Non-GAAP Tax Rate 16.1% 20.4% -4.3pts N/A Non-GAAP EPS2,3 $2.07 $1.40 +48% +54% $ in billions, except EPS amounts 15 1. Merck is providing certain 2023 and 2022 non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management believes that providing this information enhances investors’ understanding of the company’s results because management uses non-GAAP results to assess performance. Management uses non-GAAP measures internally for planning and forecasting purposes and to measure the performance of the company along with other metrics. In addition, annual employee compensation, including senior management’s compensation, is derived in part using a non-GAAP pretax income metric. This information should be considered in addition to, but not as a substitute for or superior to, information prepared in accordance with GAAP. For a description of the non- GAAP adjustments, see Table 2a attached to the earnings release. 2. Q1 2024 includes $656 million charge, or $0.26 negative EPS impact, for the acquisition of Harpoon. Q1 2023 includes charges of $1.4 billion, or $0.52 negative EPS impact, for the acquisition of Imago and collaboration agreement with Kelun-Biotech. 3. Q1 2024 GAAP EPS of $1.87. -- 15 of 33 -- Updated 2024 financial outlook 1. Guidance does not assume any additional significant potential business development transactions. 2. One royalty on KEYTRUDA stepped down from 6.5% to 2.5% on 1/1/2024; One royalty on GARDASIL of 7% expired on 1/1/2024. 16 Prior Guidance Updated Guidance Key Assumptions Revenue $62.7B to $64.2B $63.1B to $64.3B • Assumes ~3% FX headwind (previously ~2%) • Implies growth of 5% to 7% (previously 4% to 7%) Non-GAAP Gross Margin Rate ~80.5% ~81.0% • Includes the benefit from reduced royalties paid on KEYTRUDA and GARDASIL2 Non-GAAP Operating Expenses1 $25.1B to $26.1B $25.2B to $26.1B • Includes $656M one-time charge related to the acquisition of Harpoon Therapeutics Other (Income) / Expense ~$200M of expense ~$250M of expense Tax Rate ~14.5% to 15.5% ~14.5% to 15.5% Shares Outstanding ~2.54B ~2.55B • Assumes modest share repurchase Non-GAAP EPS $8.44 to $8.59 $8.53 to $8.65 • Includes one-time ~$0.26 charge related to Harpoon Therapeutics • Assumes an incremental $0.05 FX headwind • Assumes full year ~$0.30 FX headwind -- 16 of 33 -- Key modeling considerations KEYTRUDA GARDASIL • Increased sales guidance reflects continued growth from additional indications and patient demand 17 • Expect more evenly distributed quarterly shipments to China this year, which will adversely impact Q2 2024 ex-U.S. growth LAGEVRIO • Sales in Q1 2024 were driven by COVID-19 incidence in Asia-Pacific markets, and continue to anticipate lower sales than 2023 -- 17 of 33 -- WINREVAIR: Excited to bring a novel treatment option to adult patients with PAH 18 • Confident in successful launch of WINREVAIR, consistent with prior expectations • Encouraged by high interest from patient groups and a range of relevant prescribers • Several payers have already established coverage policies, while others are in the process of developing their policies • Intend to provide appropriate insights to track progress, including prescription data and revenue -- 18 of 33 -- 19 Continue to invest in the pipeline and business while augmenting the pipeline with value-enhancing business development $2.8 $0.9 $2.0 $1.1 $0.1 After-Tax R&D CapEx Dividends Paid Business Development (ex-divestitures) Share Repurchase Q1 Spend ($ in billions) Remain committed to balanced capital allocation strategy Capital allocation order of priority 1 1. Reflects R&D excluding Business Development -- 19 of 33 -- Research Update Dr. Dean Li President, Merck Research Laboratories -- 20 of 33 -- WINREVAIR (sotatercept-csrk) • Received FDA approval for WINREVAIR for treatment of adults with PAH • Currently under review by EMA with decision expected in 2H 2024 • Phase 3 ZENITH and HYPERION studies ongoing, as well as Phase 2 CADENCE study 21 Expanding the treatment landscape for patients with Pulmonary Arterial Hypertension -- 21 of 33 -- Recent Data at CROI1 22 Progress across our HIV clinical program • In collaboration with Gilead, presented positive safety and efficacy findings from Phase 2 study evaluating a once-weekly oral combination of islatravir and lenacapavir for treatment of adults living with HIV • Presented safety and tolerability data for MK-8527 from two Phase 1 trials evaluating ascending single dose and multiple doses for prophylaxis of adults 18 to 55 years old not infected with HIV 1. Conference on Retroviruses and Opportunistic Infections -- 22 of 33 -- Important updates across our vaccines programs 23 V116 HPV Vaccines • Presented positive data from multiple Phase 3 trials at ISPPD1 in March • Potential to be first approved pneumococcal conjugate vaccine specifically designed to address the majority of serotypes that cause invasive pneumococcal disease for individuals 65+2 • PDUFA set for June 17th, followed by ACIP meeting • Announced new clinical program to identify a novel multi-valent HPV vaccine candidate • Plan to initiate clinical trials evaluating short and long-term efficacy of single-dose GARDASIL 9 versus three-dose regimen 1. International Society of Pneumonia & Pneumococcal Diseases 2. According to CDC data from 2018-2021 -- 23 of 33 -- Diversifying our oncology program and executing on our strategy Precision Molecular Targeting Tissue Targeting Immuno-oncology 24 Boost anti-tumor immune responses Impact pathways that can drive cancer growth Increase cancer cell sensitivity with ADCs and immune- engagers -- 24 of 33 -- Committed to harnessing the power of immuno-oncology 25 Immuno-oncology • KEYNOTE-A18: Met primary endpoint of OS for treatment of newly diagnosed patients with high-risk locally advanced cervical cancer • KEYNOTE-868: FDA granted priority review for 1L treatment of patients with primary advanced or recurrent endometrial carcinoma (PDUFA June 21 st) • KEYNOTE-671: European Commission approved KEYTRUDA perioperative treatment regimen for certain adult patients with resectable NSCLC at high risk of recurrence -- 25 of 33 -- 26 Substantial progress across precision and tissue targeting Precision Molecular Targeting Tissue Targeting • Initiated Phase 3 trial for MK-1084, an investigational KRAS G12C inhibitor, in combination with KEYTRUDA for treatment of certain patients with metastatic NSCLC • Initiated Phase 2 / 3 REJOICE-Ovarian01 trial evaluating MK-59091 for treatment of patients with platinum-resistant ovarian cancer • Poised to initiate Phase 3 trial evaluating MK-24001 for treatment of certain patients with SCLC • Completed acquisition of Harpoon Therapeutics, with lead candidate MK-6070, a T-cell engager targeting (DLL3) being evaluated in certain patients with SCLC and neuroendocrine tumors 1. In collaboration with Daiichi Sankyo -- 26 of 33 -- Key upcoming dates 27 Save the Date: ASCO Investor Event in Chicago Upcoming U.S. Regulatory Action Dates: June 17th V116 for prevention of invasive pneumococcal disease and pneumococcal pneumonia in adults June 21st KEYTRUDA for primary advanced or recurrent endometrial carcinoma (KEYNOTE-868) June 26th MK-10221 for advanced EGFRm NSCLC (HERTHENA-Lung01) 1. In collaboration with Daiichi Sankyo. -- 27 of 33 -- Q&A Rob Davis Chairman & Chief Executive Officer Caroline Litchfield Chief Financial Officer Dr. Dean Li President, Merck Research Laboratories Peter Dannenbaum Senior Vice President, Investor Relations -- 28 of 33 -- Appendix 29 -- 29 of 33 -- Q1 2024 GAAP financial results summary 30 Q1 2024 Q1 2023 Change Change Ex-FX Sales $15.8 $14.5 +9% +12% Operating Expenses $6.5 $6.8 -4% -3% Tax Rate 15.9% 22.6% -6.7pts N/A GAAP EPS $1.87 $1.11 +68% +76% $ in billions, EPS amounts -- 30 of 33 -- $11.0 $3.7 $7.5 $17.7 $1.3 $0 $3 $6 $9 $12 $15 $18 $21 After-Tax R&D CapEx Dividends Paid Business Development (ex-divestitures) Share Repurchase Capital allocation: Trailing twelve months ~$ 18B Over 5 years, including expanding manufacturing capacity for Oncology, Vaccines, and Animal Health. Includes >$10B in the U.S. Billions $1.80 $1.84 $1.88 $1.92 $2.20 $2.44 $2.60 $2.76 $2.92 $3.08 $1.40 $1.70 $2.00 $2.30 $2.60 $2.90 $3.20 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 Dollars per share +2% +2% +2% +2% +11% +15% +7% Over the past 12 months Capital investments 2023 to 2027 Commitment to the dividend 31 Well-positioned balance sheet with capacity to fund additional value-enhancing business development opportunities +6% Order of priority +6% 1. Reflects R&D excluding Business Development 2. Includes BD payments reflected in operating cash flow 2 1 E +5% E -- 31 of 33 -- Driving value for patients and shareholders by progressing our pipeline 32 Key regulatory milestones since the last earnings call: Key data & clinical advancements since the last earnings call: • In the U.S.: o FDA accepted for priority review the sBLA for KEYTRUDA in combination with chemotherapy, followed by KEYTRUDA as a single agent for the treatment of patients with primary advanced or recurrent endometrial carcinoma based on NRG-GY018 (KEYNOTE-868) o FDA approved WINREVAIR for the treatment of adults with pulmonary arterial hypertension based on STELLAR • In the EU: o EC approved KEYTRUDA as part of a treatment regimen in the perioperative setting for the treatment of certain patients with resectable NSCLC at high risk of recurrence based on KEYNOTE-671 1. FDA approval of KEYTRUDA in combination with CRT for treatment of patients with FIGO 2014 Stage III-IVA cervical cancer 2. In collaboration with Daiichi Sankyo • Presented positive data from multiple Phase 3 studies evaluating V116, an investigational 21-valent pneumococcal conjugate vaccine for adults, at the International Society of Pneumonia and Pneumococcal Diseases • Presented results from the Phase 2 study evaluating islatravir, an investigational nucleoside reverse transcriptase translocation inhibitor, and lenacapavir, a first-in-class capsid inhibitor, in the treatment of patients with HIV at the Conference on Retroviruses and Opportunistic Infections • Announced Phase 3 KEYNOTE-A181 trial evaluating KEYTRUDA in combination with chemoradiotherapy met its primary endpoint of overall survival for the treatment of newly diagnosed patients with high-risk locally advanced cervical cancer • Announced plans to initiate clinical development of a new investigational multi-valent HPV vaccine and to conduct clinical trials evaluating whether a single-dose regimen of GARDASIL 9 provides comparable long-term protection to the approved three-dose regimen at the EUROGIN 2024 HPV Congress • Initiated Phase 3 trial evaluating MK-1084, an investigational oral selective KRAS G12C inhibitor, for the treatment of certain patients with metastatic NSCLC • Initiated Phase 2/3 REJOICE-Ovarian01 trial evaluating raludotatug deruxtecan (R-DXd)2 for the treatment of patients with platinum-resistant ovarian cancer -- 32 of 33 -- Phase 2 Phase 3 Under regulatory review Oncology V181 Dengue Virus Vaccines Infectious disease MK-8189 4 Schizophrenia Neuroscience Gefapixant (MK-7264)5 Cough (US) General medicine As of April 25, 2024 Infectious disease Oncology Oncology MK-8527 HIV-1 prevention MK-8591B (islatravir+MK-8507)1 HIV-1 infection MK-8591D (islatravir+lenacapavir)2,11 HIV-1 infection MK-1022 (patritumab deruxtecan)6 NSCLC (EU) MK-1026 (nemtabrutinib) Hematological Malignancies MK-1308A (quavonlimab +pembrolizumab) RCC MK-2870 (sacituzumab tirumotecan)7 Breast Endometrial NSCLC MK-3543 (bomedemstat) Myeloproliferative Disorders KEYTRUDA (MK-3475) CSCC (EU) Hepatocellular (EU) Mesothelioma Ovarian SCLC MK-3475A (pembrolizumab +hyaluronidase) NSCLC MK-4280A (favezelimab +pembrolizumab) CRC Hematological Malignancies MK-5684 (opevesostat)13 Prostate WELIREG (MK-6482) RCC (EU) LYNPARZA (MK-7339)8 NSCLC SCLC LENVIMA (MK-7902)9 Esophageal Gastric MK-7684A (vibostolimab +pembrolizumab) Melanoma NSCLC SCLC V940 10 Melanoma NSCLC MK-8591A (doravirine+islatravir)2 HIV-1 Infection KEYTRUDA (MK-3475) Resectable NSCLC (JPN) 1L Urothelial (EU, JPN) 1L HER2- Gastric (JPN) 1L Biliary (JPN) Endometrial Carcinoma (US, EU, JPN) Cervical (EU, JPN) MK-1022 (patritumab deruxtecan)6 NSCLC (US) WELIREG (MK-6482) Certain VHL tumors (EU) Advanced RCC (EU) MK-2060 Thrombosis MK-5475 PH-COPD MK-6024 (efinopegdutide) NASH WINREVAIR (MK-7962) Pulmonary Hypertension due to Left Heart Disease Cardiometabolic MK-4280A (favezelimab+pembrolizu mab) Bladder cSCC Endometrial Esophageal Melanoma RCC MK-5890 (boserolimab) Neoplasm Malignant MK-5909 (raludotatug deruxtecan)6 Ovarian MK-2870 (sacituzumab tirumotecan)7 Neoplasm Malignant KEYTRUDA (MK-3475) Advanced Solid Tumors Prostate KEYTRUDA (MK-3475A) cSCC MK-4280 (favezelimab) NSCLC LYNPARZA (MK-7339)8 Advanced Solid Tumors LENVIMA (MK-7902)9 HNSCC WELIREG (MK-6482) Endometrial Esophageal HCC Prostate Rare Cancers MK-7684A (vibostolimab +pembrolizumab) Biliary Bladder Breast Cervical CRC Endometrial Esophageal Gastric HCC HNSCC Ovarian Prostate RCC V940 10 Bladder RCC MK-1022 (patritumab deruxtecan)6 Gastric Melanoma MK-1308 (quavonlimab) NSCLC MK-1308A (quavonlimab +pembrolizumab) CRC MK-2140 (zilovertamab vedotin) Hematological Malignancies MK-2400 (ifinatamab deruxtecan)6 CRC SCLC Broad and innovative pipeline to address significant unmet medical needs Vaccines MK-1654 (clesrovimab) Respiratory Syncytial Virus (RSV) 1 On FDA clinical hold 2On FDA partial clinical hold for higher doses than those used in current clinical trials 3 Available in the US under EUA 4 Development is co-funded by Royalty Pharma 5FDA issued CRL in December 2023 6 In collaboration with Daiichi Sankyo 7In collaboration with Kelun-Biotech 8 In collaboration with AstraZeneca 9 In collaboration with Eisai 10In collaboration with Moderna 11In collaboration with Gilead 12Developed under an agreement with Ridgeback Bio 13 In collaboration with Orion Cardiometabolic MK-7240 (tulisokibart) Ulcerative Colitis Immunology MK-0616 Hypercholesterolemia WINREVAIR (MK-7962) Pulmonary Arterial Hypertension (EU) Cardiometabolic LAGEVRIO (MK-4482)3,12 COVID-19 antiviral Vaccines V116 Pneumococcal conjugate vaccine, adult (US, EU) MK-6194 Vitiligo Immunology -- 33 of 33 --